Ampio' subisidary establishes study collaboratoins with two research centers Ampio announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center and the University of Thessaly. These two leading oxidative stress research groups will utilize Luoxis' proprietary RedoxSYS oxidation-reduction potential diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion.
Ampio confirms sales agreement with Cantor Fitzgerald Ampio Pharmaceuticals entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. CEO Michael Macaluso stated "During our most recent conference call, we stated that we are not currently raising money and that we have enough money to get us through 2016 and into 2017 and still complete all of our current objectives and nothing has changed since that conference call. The "at-the-market" program may be used opportunistically and as a contingency facility to strengthen our position post-Ampion trial data."